Business News • PR NewsWire • IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

COPENHAGEN, Denmark, Feb. 25, 2020 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the successful outcome of a scheduled interim analysis of the ongoing...

View More : https://www.prnewswire.com:443/news-releases/io-biotech-announces-positive-outcome-of-interim-analysis-of-phase-2-random...

Releted News by prnewswire

Visure Solutions Offers Limited Free Subscription License for its Acclaimed Visure Web Reviewer Tool

Covariant and ABB Partner to Deploy Integrated AI Robotic Solutions

Nippon Express USA Relocates Warehouse to Long Beach (Los Angeles)